knowledge -WSS

knowledge

author：hotspot 2025-09-27 12:48:30 - browse：997

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug Krazati, for $4.8 billion in cash in a deal that shows the continued interest of large pharmaceutical firms in relatively small “bolt-on” acquisitions.

Bristol said that it would pay $58.00 per share for Mirati, and would hold another $12.00 per share, or a total of $1 billion, to be paid if one of two different applications for an additional use for Krazati is approved within seven years after the merger closes.

Chris Boerner, Bristol’s chief operating officer and CEO-elect, said in a statement that Mirati had several cancer drugs in development that could deliver sales in the latter half of the decade and beyond, when investors worry that Bristol will need new products to sustain its growth.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： How Long Island became the ‘eugenics capital of the world’

WSS

Sudafed saga points to U.S. issues with evaluating older drugs

Did you have Obamacare on your GOP debate bingo card?

Australia’s approach to dialysis celebrates life

Biogen shutters digital health group, ends Apple study, in cost cutting move

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

In science, is the line between industry and academia shifting?

hotspot

knowledge

leisure time

DIEP, the 'gold standard' of breast reconstruction, is under threat

What AAP's gender

Wildfire smoke exposes gaps in outdoor worker protections

How a symptom of dementia informs our understanding of creativity

Affirmative action in medical school literally saved lives

Complete sequence of Y chromosome published for first time

What does generative AI mean for health care? We asked experts

Psilocybin's anti

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Apellis safety probe of eye disease drug centers on injection needle

knowledge

Did you have Obamacare on your GOP debate bingo card?

Data show record exodus of life scientists from academia

AstraZeneca challenges Medicare drug negotiation program

Diversity in medical illustrations gets boost from Chidiebere Ibe

Mindstrong's demise and the future of mental health care

Kaiser Permanente unions announce official strike date

Wikipedia

Wikipedia

hotspot

focus